ReviewRSC advances2026
Emerging trends and structure-activity insights of Schiff base-lanthanide complexes as antibacterial agents.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Design, synthesis, antibacterial activity, andRSC advances · 2026Article
- A Pyrimidine-Based Schiff Base Fluorescent Chemosensor for Selective Detection of Mg²⁺: Synthesis, Real Water Analysis, Antibacterial, DFT and Molecular Docking Study.Journal of fluorescence · 2026Article
- Synthesis and characterization of a new N4-Schiff base its zinc halide/pseudohalide complexes with thermal, antimicrobial, antioxidant, anticancer, DNA cleavage and wound healing properties.Scientific reports · 2026Article
- Antimicrobial, antibiofilm, antioxidant activities and molecular docking of Schiff base and its complexes of Cu(II), Co(II), Ni(II), Mn(II) and UOScientific reports · 2026Article
- Synthesis and multipurpose assessment of Cu(II) and Pd(II) Schiff base complexes as catalysts and antimicrobial agents.Scientific reports · 2026Article
- Schiff base metal complexes as emerging therapeutics against antimicrobial-resistant skin pathogens.ADMET & DMPK · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid escalation of microbial resistance has accelerated the search for next-generation antibacterial agents with novel mechanisms of action. Schiff bases and their lanthanide complexes have emerged as promising candidates due to their tunable structures, coordination versatility and enhanced bioactivity upon metal binding. While earlier reviews laid the foundational understanding of antibacterial activity of Schiff bases and their metal complexes, this review advances the field by offering a data-driven, mechanistically informed and structure-activity-focused perspective on the most recent antibacterial findings (2018-2025) of Schiff bases and their Ln(iii) complexes. In this review article, we critically compare the antibacterial performance of diverse ligand frameworks with lanthanide ions, under varied experimental conditions against both Gram-negative and Gram-positive bacterial strains highlighting trends in structure-activity correlations. We also identify clear trends: Schiff base ligands alone usually show modest or weak antibacterial activity, which is significantly enhanced upon complexation with lanthanide ions. Additionally, unresolved challenges, including toxicity, bioavailability and resistance modulation are discussed alongside proposed future research pathways. This perspective aims to guide the rational design of Schiff base-lanthanide complexes toward clinical translation as potent antibacterial agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.